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INTRODUCTION.
DIABETIC MELLITUS
Diabetic  millets  often  referred  to  simply  as  diabetes  (Ancient
Greek:  diabetes”  to  pass  through  [urine]”)  is  a  syndrome  of  disorder
metabolism, usually due to a combination of hereditary and environment causes,
resulting in abnormally high blood sugar level (hyperglycemia) 
Diabetes is described as starvation in the midst of plenty. Because the body will
have high amount of glucose level but the cells are incapable of consume it
because of osmotic difference
Insulin  is  a  hormone  produced in  the  pancreas,  which  enable  body cells  to
absorb glucose, to turn into energy. If the body cells cannot absorb the glucose,
the  glucose  accumulates  in  the  blood  (hyperglycemia),  leading  to  various
potential medical complications. 
TYPES OF DIABETES MELLITUS.
The type of diabetes is based on the presumed etiology they are
1. Type 1 diabètes or Insulin dependent diabetes mellitus (IDDM)
2.  Type  2  diabètes  or  Non  Insulin  dependent  diabetes  mellitus  
(NIDDM)
3. Gestational Diabetes (Pregnancy diabetic).
1. TYPE 1 DIABETES
Insulin-dependent (Type I) diabetes mellitus is a chronic disease
characterized by hyperglycemia, impaired metabolism and storage of important
nutrients,  evidence  of  autoimmunity,  and  long-term vascular  and neurologic
complications.
 Insulin secretary function is limited. Cell membrane binding is not
primarily involved. The goal of treatment is to relieve symptoms and to achieve
blood  glucose  levels  as  close  to  normal  as  possible  without  severe
hypoglycemia. However, even with education and self-monitoring of the blood
glucose level, attaining recommended target values (plasma glucose level less
than 8.0 mmol/L before main meals for adults) remains difficult.
. Therapy with one or two injections per day of mixed short-acting
or  intermediate-acting  insulin  preparations  is  a  compromise  between
convenience and the potential for achieving target plasma glucose levels.
 Intensive  insulin  therapy  with  multiple  daily  injections  or
continuous infusion with an insulin pump improves mean glycated hemoglobin
levels;  however,  it  increases rates  of severe hypoglycemia and has not been
shown  to  decrease  the  incidence  of  clinically  significant  renal,  retinal  or
neurologic  dysfunction.  Future  prospects  include  automated  techniques  of
insulin delivery, immunosuppressant to preserve endogenous insulin secretion
and islet transplantation.
Type 1 diabetes (IDDM) is characterized by loss of the insulin producing
beta cells of the islet of Langerhans in the pancreas leading deficiency. In type 1
diabetes,  the body does not produce insulin,  and daily insulin injections are
required.  Type  1  diabetes  is  usually  diagnosed  during  childhood  or  early
adolescence and it affects about 1 in every 600 children.
It has two forms:
Immune  Mediated  Diabetes  Mellitus:  Results  from  a  cellular  mediated
autoimmune destruction of the beta cells of the pancreas.
Idiopathic Diabetes Mellitus: Refer to forms of the disease that have unknown
etiologies.
The majority of diabetes 1 is of the immune medicated in nature, where beta
cells loss is a T cell mediated auto immune attack.
SYMPTOMS OF TYPE 1 DIABETIC
Type 1 diabetes signs and symptoms can come on quickly and may include:
• Increased thirst and frequent urination
• Extreme hunger
• Weight loss
• Fatigue
• Blurred vision
CAUSES OF TYPE 1 DIABETIC.
The exact cause of type 1 diabetes is unknown. In most people with type 1
diabetes,  the  body's  own  immune  system  which  normally  fights  harmful
bacteria and viruses mistakenly destroys the insulin-producing (islet) cells in the
pancreas.  Genetics  may play a  role  in  this  process,  and exposure  to  certain
viruses may trigger the disease.
1) A family history. Anyone with a parent or sibling with type 1 diabetes
has a slightly increased risk of developing the condition.
2) Genetics. The presence of certain genes indicates an increased risk of de-
veloping type 1 diabetes. In some cases — usually through a clinical trial
genetic testing can be done to determine if someone who has a family his-
tory of type 1 diabetes is at increased risk of developing the condition.
3) Geography. The incidence of type 1 diabetes tends to increase as you
travel away from the equator. People living in Finland and Sardinia have
the  highest  incidence of  type  1  diabetes  — about  two  to  three  times
higher than rates in the United States and 400 times that of people living
in Venezuela
4) Viral exposure. Exposure to Epstein-Barr virus, coxsackievirus, mumps
virus or cytomegalovirus may trigger the autoimmune destruction of the
islet cells, or the virus may directly infect the islet cells.
5) Early vitamin D. Research suggests that vitamin D may be protective
against type 1 diabetes. However, early drinking of cow's milk — a com-
mon source of vitamin D — has been linked to an increased risk of type 1
diabetes.
6) Other dietary factors. Omega-3 fatty acids may offer some protection
against  type 1  diabetes.  Drinking  water  that  contains  nitrates  may in-
crease the risk. Consuming dairy products, particularly cow's milk, may
increase infants' risk of the disease. Additionally, the timing of the intro-
duction  of  cereal  into a baby's  diet  may affect  risk.  One clinical  trial
found that between ages 3 and 7 months appears to be the optimal time
for introducing cereal.
COMPLICATIONS OF TYPE 1 DIABETIC
Type 1 diabetes can affect major organs in your body, including
heart,    blood vessels, nerves, eyes and kidneys. Keeping the blood sugar
level close to normal most of the time can dramatically reduce the risk of
many complications.
Long-term  complications  of  type  1  diabetes  develop  gradually,
over years. The earlier you develop diabetes — and the less controlled your
blood  sugar  the  higher  the  risk  of  complications.  Eventually,  diabetes
complications may be disabling or even life-threatening.
1) Heart  and blood vessel  disease. Diabetes  dramatically  increases  your
risk of various cardiovascular problems, including coronary artery disease
with chest pain (angina), heart attack, stroke, narrowing of the arteries
(atherosclerosis) and high blood pressure.
2) Nerve damage (neuropathy). Excess sugar can injure the walls of the
tiny blood vessels (capillaries) that nourish your nerves, especially in the
legs. This can cause tingling, numbness, burning or pain that usually be-
gins  at  the  tips  of  the  toes  or  fingers  and  gradually  spreads  upward.
Poorly controlled blood sugar could cause you to eventually lose all sense
of feeling in the affected limbs. Damage to the nerves that affect the gas-
trointestinal tract can cause problems with nausea, vomiting, diarrhea or
constipation. For men, erectile dysfunction may be an issue.
3) Kidney damage (nephropathy). The  kidneys  contain  millions  of  tiny
blood vessel clusters that filter waste from your blood. Diabetes can dam-
age this delicate filtering system. Severe damage can lead to kidney fail-
ure or irreversible end-stage kidney disease, which requires dialysis or a
kidney transplant.
4) Eye damage. Diabetes can damage the blood vessels of the retina (dia-
betic  retinopathy),  potentially  leading  to  blindness.  Diabetes  also  in-
creases the risk of other serious vision conditions, such as cataracts and
glaucoma.
5) Foot damage. Nerve damage in the feet or poor blood flow to the feet in-
creases the risk of various foot complications. Left untreated, cuts and
blisters can become serious infections. Severe damage might require toe,
foot or even leg amputation.
6) Skin and mouth conditions. Diabetes may leave you more susceptible to
skin problems, including bacterial and fungal infections. Gum infections
also may be a concern, especially if you have a history of poor dental hy-
giene.
7) Osteoporosis. Diabetes may lead to lower than normal bone mineral den-
sity, increasing your risk of osteoporosis.
8) Pregnancy complications. High blood sugar levels can be dangerous for
both the mother and the baby. The risk of miscarriage, stillbirth and birth
defects are increased when diabetes isn't well controlled. For the mother,
diabetes increases the risk of diabetic ketoacidosis, diabetic eye problems
(retinopathy), pregnancy-induced high blood pressure and preeclampsia.
9) Hearing  problems. Hearing  impairments  occur  more  often  in  people
with diabetes.
TREATMENT FOR TYPE 1 DIABETES 
 Exercising regularly and maintaining a healthy weight
 Eating healthy foods
 Monitoring blood sugar
 Taking insulin
The goal is to keep the blood sugar level as close to normal as possible to delay
or prevent complications. Although there are exceptions, generally, the goal is to
keep your daytime blood sugar levels before meals between 80 and 120 mg/dL
(4.4 to 6.7 mol/L) and your bedtime numbers between 100 and 140 mg/dL (5.6
to 7.8 mol/L).
INSULIN
Insulin  is  a  peptide  hormone,  produced  by  the  beta  cells  of
pancreas and is central to regulate the blood glucose level in the body. Patient
with type 1 diabetic insulin cannot be secreted in their body (pancreas). So it
(insulin) must be injected externally. Depends on their blood glucose level.
Table: 1-TYPES OF INSULIN  
Each insulin has on own
Type of Insulin BrandName Generic Name Onset Peak Duration
Rapid-acting
NovoLog Insulin aspart 15 minutes 30 to 90
minutes 3 to 5 hours
Apidra Insulinglulisine 15 minutes
30 to 90
minutes 3 to 5 hours
Humalog Insulin lispro 15 minutes 30 to 90
minutes 3 to 5 hours
Short-acting
Humulin R
Regular (R) 30 to 60
minutes 2 to 4 hours 5 to 8 hoursNovolin R
Intermediate-
acting
Humulin N NPH (N) 1 to 3 hours 8 hours 12 to 16 hoursNovolin N
Long-acting Levemir Insulin detemir 1 hour Peakless 20 to 26 hoursLantus Insulin glargine
Pre-mixed NPH
(intermediate-
acting)
and regular
(short-acting)
Humulin
70/30
 Novolin
70/30
70% NPH and
30% regular
30 to 60
minutes Varies 10 to 16 hours
Humulin
50/50
50% NPH and
50% regular
30 to 60
minutes Varies 10 to 16 hours
Pre-mixed
insulin lispro
protamine
suspension
(intermediate-
acting) and
insulin lispro
(rapid-acting
Humalog
Mix 75/25
75% insulin
lispro
protamine and
25% insulin
lispro
10 to 15
minutes Varies 10 to 16 hours
Humalog
Mix 50/50
50% insulin
lispro
protamine and
50% insulin
lispro
10 to 15
minutes Varies 10 to 16 hours
Pre-mixed
insulin aspart
protamine
suspension
(intermediate-
acting) and
insulin aspart
(rapid-acting)
NovoLog
Mix 70/30
70% insulin
aspart
protamine
and 30%
insulin aspart
5 to 15
minutes Varies 10 to 16 hours
 Peak
 Duration time.
• Onset is how soon the insulin starts a lower the blood glucose 
• The peak is the time the insulin is working the hardest to lowering the  
blood glucose level.
• Duration is the time at how long the insulin lasts the length to  keeps low-
ering the blood sugar
The chart shows the different insulin has different onset, duration and peak.
2. TYPE 2 DIABETES
Type 2 diabetes, once known as adult-onset or noninsulin-depen-
dent diabetes, is a chronic condition that affects the way your body metabolizes
sugar (glucose), your body's main source of fuel.
With type 2 diabetes, your body either resists the effects of insulin
— a hormone that regulates the movement of sugar into your cells — or doesn't
produce enough insulin to maintain a normal glucose level. Untreated, type 2 di-
abetes can be life-threatening.
It is the result of failure to produce sufficient insulin and insulin
resistance. Elevated blood glucose levels are managed with reduced food intake,
increased physical activity, and eventually oral medications or insulin
SYMPTOMS OF TYPE 2 DIABETES
Type 2 diabetes symptoms may develop slowly
1) Increased thirst and frequent urination
2) Increased hunger. 
3) Weight loss. 
4)  Fatigue
5) Blurred vision. 
6) Slow-healing sores or frequent infections.  
CAUSES TYPE 2 DIABETES
1) Weight. Being overweight is a primary risk factor for type 2 diabetes.
The more fatty tissue you have, the more resistant your cells become to
insulin.
2) Fat distribution. If your body stores fat primarily in your abdomen,
your risk of type 2 diabetes is greater than if your body stores fat else-
where, such as your hips and thighs.
3) Inactivity. The less active you are, the greater your risk of type 2 dia-
betes. Physical activity helps you control your weight, uses up glucose
as energy and makes your cells more sensitive to insulin.
4) Family history. The risk of type 2 diabetes increases if your parent or
sibling has type 2 diabetes.
5) Race. Although it's unclear why, people of certain races — including
blacks, Hispanics, American Indians and Asian-Americans — are more
likely to develop type 2 diabetes than whites are.
6) Age. The risk of type 2 diabetes increases as you get older, especially
after age 45. That's probably because people tend to exercise less, lose
muscle mass and gain weight as they age. But type 2 diabetes is also
increasing  dramatically  among  children,  adolescents  and  younger
adults.
7) Prediabetes. Prediabetes is a condition in which your blood sugar level
is higher than normal, but not high enough to be classified as diabetes.
Left untreated, prediabetes often progresses to type 2 diabetes.
COMPLAINTS TYPE 2 DIABETES
1) Heart and blood vessel disease. Diabetes dramatically increases the
risk of various cardiovascular problems, including coronary artery dis-
ease with chest pain (angina), heart attack, stroke, narrowing of arteries
(atherosclerosis) and high blood pressure. The risk of stroke is two to
four times higher for  people with diabetes,  and the death rate from
heart disease is two to four times higher for people with diabetes than
for people without the disease, according to the American Heart Asso-
ciation.
2) Alzheimer's  disease. Type  2  diabetes  may  increase  the  risk  of
Alzheimer's  disease  and  vascular  dementia.  The  poorer  your  blood
sugar control, the greater the risk appears to be. So what connects the
two conditions? One theory is that cardiovascular problems caused by
diabetes could contribute to dementia by blocking blood flow to the
brain or causing strokes. Other possibilities are that too much insulin in
the blood leads to brain-damaging inflammation, or lack of insulin in
the brain deprives brain cells of glucose.
3) Nerve damage (neuropathy). Excess sugar can injure the walls of the
tiny blood vessels (capillaries) that nourish your nerves, especially in
the legs. This can cause tingling, numbness, burning or pain that usu-
ally begins at the tips of the toes or fingers and gradually spreads up-
ward. Poorly controlled blood sugar can eventually cause you to lose
all sense of feeling in the affected limbs. 
4) Kidney damage (nephropathy). The kidneys contain millions of tiny
blood vessel clusters that filter waste from your blood. Diabetes can
damage this delicate filtering system. Severe damage can lead to kid-
ney failure or irreversible end-stage kidney disease, requiring dialysis
or a kidney transplant.
5) Foot damage. Nerve damage in the feet or poor blood flow to the feet
increases the risk of various foot complications. Left  untreated, cuts
and blisters can become serious infections. Severe damage might re-
quire toe, foot or even leg amputation.
6) Skin and mouth conditions. Diabetes may leave you more susceptible
to skin problems, including bacterial and fungal infections. Gum infec-
tions also may be a concern, especially if you have a history of poor
dental hygiene.
TREATMENT TYPE 2 DIABETES.
Diabetes  mellitus  type  2  is  a  chronic,  progressive  disease  that  has  nl
established  cure,  but  does  have  well-  established  which  can  delay  and
sometimes  which  can  delay  and  sometimes  avoid  most  of  the  formerly
inevitable of the condition.
They are two main goals of treatment.
 Reduction of morality and concomitant morbidity (from as-
sorted diabetic complication
 Preservation of quality of life.
Oral hypoglycemic drugs are used to maintain the blood glucose level  for some
patient I have to take both oral drug and with insulin.
ORAL HYPOGLYCEMIC DRUGS.
a. Sulphonyl ureas   –
1. First generation
i. Tolbutamide
ii. Chlorpropamide
2. Second generation 
i. Glibenglamide
ii. Glipizide
iii. Gliclazide and Glimiperide
b. Biguanides
1. Metformin
c. Meglitinides
a. Repaglinide
b. Nateglinide
d. Thiazolidine diones – 
a. Rosiglitazone
b. Pioglitazone
e. Alpha glucosidase inhibitors   
Acarbose, Miglitol
Mechanism of action.
Sulfonylurea’s  bind  to  (KATP)  channel  on  the  cell  membrane  of
pancreatic this  inhibits  a  tonic,  hyperpolarizing  efflux  of  potassium,  thus
causing  the  electric  potential  over  the  membrane  to  become  more  positive.
This opens voltage-gated channels. The rises in intracellular calcium leads to
increased fusion of granulate with the cell membrane, and therefore increased
secretion of (pro) insulin.
Tolbutamide
Tolbutamide is  a  first  generation This  drug  may  be  used  in  the
management  of if diet  alone  is  not  effective.  Tolbutamide  stimulates  the
secretion of by the. Since the pancreas must synthesize insulin in order for this
drug to work, it is not effective in the management of. It is not routinely used
due  to  a  higher  incidence  of  adverse  effects  compared  to  newer  second
generation sulfonylurea’s, such as it generally has a short duration of action due
to its rapid metabolism, and is therefore safe for use in elderly diabetics.
Glimiperide.
The  primary  mechanism  of  action  of  glimepiride  in  lowering  blood
glucose  appears  to  be  dependent  on  stimulating  the  release  of  insulin  from
functioning pancreatic beta cells. In addition, extrapancreatic effects may also
play a role in the activity of sulfonylureas such as glimepiride. This is supported
by  both  preclinical  and  clinical  studies  demonstrating  that  glimepiride
administration can lead to increased sensitivity of peripheral tissues to insulin.
These findings are consistent with the results of a long-term, randomized, and
placebo-controlled  trial  in  which  AMARYL therapy  improved  postprandial
insulin/C-peptide  responses  and  overall  glycemic  control  without  producing
clinically meaningful increases in fasting insulin/C-peptide levels. However, as
with other sulfonylureas,  the mechanism by which glimepiride lowers  blood
glucose during long-term administration has not been clearly established.
Glibenglamide.
The  drug  works  by  binding  to  and  activating  the regulatory  subunit  of
the  (KATP). This inhibition causes cell membrane opening. This results in an in-
crease in intracellular in the and subsequent stimulation insulin release.
After a cerebral ischemic insult is broken and glibenclamide can reach the cen-
tral nervous system. Glibenclamide has been shown to bind more efficiently to
the ischemic hemisphere. Moreover, under ischemic conditions SUR1, the regu-
latory subunit of the KATP- and the NCCa-ATP-channels, is expressed in neurons,
atrocities, oligodendrocytes, endothelial cells and by reactive microglia.
Gliclazide
Gliclazide selectively binds to sulfonylurea receptors on the surface of the
pancreatic beta-cells. It was shown to provide cardiovascular protection as it 
does not bind to sulfonylurea receptors (n the heart This binding effectively 
closes the K+ ion channels. This decreases the efflux of potassium from the cell 
which leads to the depolarization of the cell. This causes voltage dependent Ca+
+ ion channels to open increasing the Ca++ influx. The calcium can then bind to
and activate calmodulin which in turn leads to exocytose of insulin vesicles 
leading to insulin release
Metformin
Metformin  activates  AMP  activated  protein  kinase  (AMPK)  a  liver
enzyme that play an important role in signaling whole body energy balance and
the glucose and fats activation of AMPK  is required for Metformin inhibitory
effects on the production of liver glucose.
Repaglinide. 
Repaglinide acts by stimulating release of insulin from the cells of the
islets of pancreas inhibiting ATP-sensitive K+ channels, thereby activating the
Ca++  channels  with  increase  in  intracellular  calcium  to  release
insulin. However,  repaglinide  acts  on  a  different  binding  site  than  the
sulphonylureas. Repaglinide is not effective in the absence of functioning beta-
cells.  Repaglinide  increases  the  amount  of  insulin  released  in  a  natural  and
physiological  pulsatile  pattern  the  activity  of  repaglinide  is  dose-dependent.
Mean insulin levels begin to rise approximately 1.5 hours after the pre-prandial
dose of repaglinide and declines towards baseline levels between meal-time the
rapid  onset  of  action  and  the  short  duration  of  hypoglycemic  effect  of
repaglinide makes this agent suitable for pre-prandial administration. The main
advantage of pre-prandial administration is that patients can miss or postpone a
meal (and the corresponding repaglinide dose) without increasing the risk of
hypoglycemia or compromising glycaemic control.
Pioglitazone.
 Pioglitazone is an oral drug that reduces the amount of glucose (sugar) in the
blood. It is in a class of anti-diabetic drugs called thiazolidinediones that are
used in the treatment .The other member in this class is . (Another member of
this class, troglitazone or Rezulin, was removed from the market because of .)
Patients with type 2 diabetes cannot make enough insulin, and the cells of their
body respond less to the insulin that is produced. Since insulin is the hormone
that stimulates cells to remove glucose from the blood, the reduced amount of
insulin and its reduced effect cause cells to take up less glucose from the blood
and the level of glucose in the blood to rise. Pioglitazone often is referred to as
an  "insulin  sensitizer"  because  it  attaches  to  the  insulin  receptors  on  cells
throughout  the  body  and  causes  the  cells  to  become  more  sensitive  (more
responsive) to insulin. As a result, more glucose is removed from the blood, and
the level of glucose in the blood falls. At least some insulin must be produced
by the pancreas in order for pioglitazone to work. Pioglitazone also lowers the
level  of  glucose  in  the  blood  by  reducing  the  production  and  secretion  of
glucose into the blood by the liver. In addition, pioglitazone may alter the blood
concentrations  of  lipids  (fats)  in  the  blood.  Specifically,  it  decreases  and
increases the "good" (HDL) 
Acarbose.
Acarbose inhibits enzymes, specifically, enzymes in the brush border of
the small intestines and pancreatic alpha-amylase hydrolyzes complex starches
to in the lumen of the small intestine, whereas the membrane-bound intestinal
alpha-glucosidase in  the  small  intestine.  Inhibition  of  these  enzyme  systems
reduces  the  rate  of  digestion  of  complex  carbohydrates.  Less  glucose  is
absorbed because the carbohydrates are not broken down into glucose molecule.
III) GESTATIONAL DIABETES
This type affects females during pregnancy. Some women have very high
levels of glucose in their blood, and their bodies are unable to produce enough
insulin to transport all of the glucose into their cells, resulting in progressively
rising  levels  of  glucose.  Diagnosis  of  gestational  diabetes  is  made  during
pregnancy.
The majority of  gestational  diabetes  patients  can  control  their  diabetes  with
exercise and diet. Between 10% to 20% of them will need to take some kind of
blood-glucose-controlling medications. Undiagnosed or uncontrolled gestational
diabetes can raise the risk of complications during childbirth. The baby may be
bigger than he/she should be.
COMPLICATIONS GESTATIONAL DIABETES
i. Increased risk of prenatal mortality and morbidity.
ii. Obesity or impaired glucose intolerance in the offspring ac-
companied by macrosomia
iii. Neural tube defects
iv. Prematurity syndromes
CAUSES GESTATIONAL DIABETES.
 Age > 30 years, obesity (BMI > 27.3 kg/m2), family history of diabetes,
glycosuria, previous macrosomia, previous congenital malformation, previous
stillbirth, past history of Gestational diabetes mellitus.
TESTES FOR DIABETIC
• Glycated hemoglobin (HbA1C) test. This blood test indicates your aver-
age blood. The term HbA1c refers to Glycated hemoglobin. It develops
when hemoglobin a protein within red blood cells that carrier’s oxygen
throughout the body. Joins in the blood becomes “Glycated” by measur-
ing Glycated hemoglobin (HbA1c), clinicians are able to get an overall
picture of what is the average blood sugar level have been over a period
of week or month
• .Random blood sugar test. A blood sample will be taken at a random
time.  Blood  sugar  values  are  expressed  in  milligrams  per  deciliter
(mg/dL) or mill moles per liter (mmol/L). Regardless of when you last
ate, a random blood sugar level of 200 mg/dL (11.1 mmol/L) or higher
suggests  diabetes,  especially  when coupled  with  any of  the  signs  and
symptoms of diabetes, such as frequent urination and extreme thirst.
• Fasting  blood  sugar  test. A  blood  sample  will  be  taken  after  an
overnight  fast.  A fasting  blood  sugar  level  less  than  100  mg/dL (5.6
mmol/L) is normal. A fasting blood sugar level from 100 to 125 mg/dL
(5.6  to  6.9  mmol/L)  is  considered  prediabetes.  If  it's  126  mg/dL (7
mmol/L) or higher on two separate tests, you have diabetes.
DIABETIC INDUCED BY STREPTOZOTOCIN.
Streptozotocin is a toxic glucose analogue that preferentially accumulates
in  pancreatic  beta  cells  via  the  GLUT2  glucose  transporter.  Especially  the
Streptozotocin inhibits insulin secretion and causes a state of insulin dependent
diabetes  mellitus.  Both  effects  can  be  attributed  to  its  specific  chemical
properties, namely its alkylating potency as with Streptozotocin  its  beta  cell
specificity is mainly the result of selective cellular uptake and accumulation.
Beta cells selectivity of    Streptozotocin  
Streptozotocin   is a nitrosourea analogue in which the N methyl N
nitrosourea (MNU) moiety is linked to the carbon 2 of a hexose. The action of
Streptozotocin  and  chemically  related  alkylating  compounds  requires  their
uptake into the cells. Nitrosourea are usually lipophilic and tissue uptake to a
plasma  membrane  in  rapid;  hour  as  a  result  of  the  hexose  substitution,  
Streptozotocin  is  less  lipophilic.  Streptozotocin  is  selectively
accumulated  in  pancreatic  β  cells  via  the  low-  affinity  GLUT2  glucose
transporter in the plasma membrane. Thus, insulin-producing cells they do not
express this glucose transporter are resistant to Streptozotocin. This observation
also explains the greater toxicity of Streptozotocin compared with N- methyl-N-
nitrosourea  in  cells  that  express  GLUT2,  even  though  both  substances
alkylating  DNA to  a  similar  extent.  The  importance  of  the  GLUT2 glucose
transporter in this process is also shown by the observation that Streptozotocin
damages other organs expressing this transporter, particularly kidney and liver.
β cells toxicity
 It is generally assumed that the toxicity of Streptozotocin is dependent up on
the DNA alkylating activity of this methylnitrosourea moiety especially at the 6
position  of  guanine.  The  transfer  of  the  methyl  group  Streptozotocin  DNA
molecules causes damage, which along a define chain of events, results in the
fragmentation  of  the  DNA.  Protein  glycosylation  may  be  an  additional
damaging factor. In the attempt to repair DNA polymerase is over stimulated.
This diminishes cellar NAD+ and subsequently ATP Ultimately responsible for
beta  cell  death,  but  it  is  likely  that  protein  methylation  contributed  to  the
functional defects of the beta cells after exposure to Streptozotocin
Inhibition of insulin secretion by Streptozotocin
 The effects of Streptozotocin on glucose and insulin homeostasis reflect the
toxin induced abnormalities in beta cell function. Initially biosynthesis, glucose
induced insulin secretion and glucose metabolism is all affected. On the other
hand  Streptozotocin  has  no  immediate  direct  inhibitory  effect  upon  glucose
transport or upon glucose stage of transport or upon glucose phosphorylation by
glucokinase.  However  at  later  stages  of  functional  beta  cells  impairment
deficiencies  in  teams  of  gene expression and protein  production  lead  to  the
deterioration of both glucose transport and metabolism 
Even  before  the  negative  effect  of  mitochondrial  DNA and  protein
alkylation and glycosylation become evident Streptozotocin induced depletion
of NAD may result in the inhibition of insulin biosynthesis and secretion later
inhibition of  glucose induced and amino acid induced insulin secretion as  a
result  of  mitochondrial  genome  become  apparent.  This  impairment  is  more
marked for nutrient that for non nutrient insulin secretion. This interpretation
has been confirmed through studies which have shown that pre treatment of
isolated pancreatic islet with polymerase inhibitor nicotinamide prevents early
inhibition  of  beta  cells  function  beta  cell  function  during  first  day  after
Streptozotocin exposure while long term inhibition of insulin secretion 6 days
after Streptozotocin exposure
MECHANISM OF ACTION OF STREPTOZOTOCIN.
STZ
Enter beta cells
Via glucose transporter
Alkylation of DNA
Activity of poly ADP ribosylation
Depletion of NAD and ATP
Enhance ATP dephosphorylation
Super oxide radicals
Hydrogen peroxide free radical
Hydroxyl radicals
Liberate toxic amount of NO 
DNA damage 
Hyperglycemia and hypoinsulinemia
HERBAL MEDICINE TODAY
In  recent  years,  there  has  been renewed interest  in  the  treatment
against different diseases using herbal drugs as they are generally non-
toxic  and  World  Health  Organization  has  also  recommended  the
evaluation of the effectiveness of plants in condition where we lack safe
modern drugs. Plant derivatives with hypoglycemic properties have been
used in folk medicine and traditional healing systems around the world
from very ancient time. Despite the introduction of hypoglycemic agents
from  natural  and  synthetic  sources,  diabetes  and  its  secondary
complications continue to be a major medical problem to people (Ravi et
al.,  2005).  Medicinal  plants  used  to  treat  hypoglycemic  and
hyperglycemic  conditions  are  of  considerable  interest  to ethno
botanical community as they are recognized to contain valuable medicinal
properties in different parts of the plant.
In  traditional  medicine  diabetes  mellitus  is  treated  with  diet,  physical
exercise  and medicinal  plants,  even though,  more  than  1200 plants  are
used  around  the  world  in  the  control  of  diabetes  mellitus  and
approximately  30%  of  the  traditionally  used  ant  diabetic plants  were
pharmacologically  and  chemically  investigated  (Alarcon-Aguilar  et  al.,
2002). On the other hand, potential hypoglycemic agents have also been
detected for more than 100 plants used in ant diabetic therapy. Traditional
treatments may provide the valuable clues for the development of new oral
hypoglycemic  agents  and  simple  dietary  adjuncts.  More  than  100
medicinal  plants  are  mentioned  in  the  Indian  system  of  medicines
including  folk  medicines  for  the  management  of  diabetes,  which  are
effective either separately or in combinations 
LITERATURE REVIEW
Sivakumar.P et  al  (2001)   was  investigated  the  anti  tumor  activity  of  the
triumfetta rhomboidea in the methanol extract in the albino mice. The METR
administrated at the doses of 100, 200 and 400 mg/kg of the plant extract in
mice bearing for 14 days after 24 hours of the tumor induction. The effects of
METR on the growth of the marine tumor, life span of EAC bearing mice were
also estimated treatment with METR brought back the hematological parameter
more  or  less  normal  level.  We  have  performed  molecular  dynamics  (MD)
simulation  and  Concord  calculation  on  the  LOV2  domain  of   triumfetta
rhomboidea with the goal of detect possible superoxide dismutase (SOD) and
Catalase  (CAT).  The  present  work  indicates  that  the  methanol  extract  of
triumfetta  rhomboidea  exhibited  significant  of  antitumor  and  antioxidant
activity in vivo
K.P.Lissy*et.al.(2006) was investigated the ANTIOXIDANT POTENTIAL of
triumfetta rhomboidea (root) they were collected the methanolic extract of the
plant leafs. From that they have been prepared the dose of 100mg/kg, 200mg/kg
and 400mg/kg and thus have been studied by using Wistar mice. The cancer has
been introduced to the animal the maximum activity of the extract has been
achieved by the methanolic extract of the plant leafs
Muhammad Iqbal et al (2010) Coal-smoke emissions affected photosynthesis,
N-metabolism  and  growth  characteristics  of  Triumfetta  rhomboidea,  as
observed at pre-flowering, flowering and post-flowering stages of plant growth.
The  netphotosynthetic  rate  and  stomata  conductance  decreased,  whereas
intercellular CO2 concentration increase dander pollution stress. The amounts
of  photosynthetic  pigments  in  leaves  were  consistently  less,  up  to  35% for
chlorophylls  and  84%  for  carotenoids.  Nitrate  level  was  raised  while  NR
activity  and  protein  contents  in  leaves  declined  at  the  polluted  site  at  each
growth stage. Sugar content was always lower at the polluted site in roots and
stem but  sizably  higher  in  leaves,  thus  showing a  failure  of  the  process  of
photosynthetic  translocation.  The  sulphur  level  in  roots,  stem  and  leaves
increased consistently. The leaf area was conspicuously reduced, leading to a
significant loss in the total  photosynthetic surface, despite an increase in the
stem length and the
Ghodosara V.P et.al(2010)   was proofed the the anti bacterial activity of the
ethanolic  extract  of  the  triumfetta  rhomboidea.  the  ethanolic  activity  of  the
extract is investigated in the albino mice it may gives positive Knollar’s and
Libermann Burchred test and the colour produced was typical of triterpences.
The  IR  spectrum  produced  similar  to  triteropences,  IR  spectrum  in  the
fundamental  region  also  supported  triterpense  structure  as  the  bands  were
noticed due to O H stretching.
Z naturforsh C et. Al (2003) was studied the mechanism of signal transduction
from the LOV domain toward the kinase region of phototropin os still not well
understood.  We  have  performed  molecular  dynamics  (MD)  simulation  and
Concord calculation on the LOV2 domain of  triumfetta rhomboidea with the
goal of detect possible difference between the two forms of the LOV domain
which  may  nit  show up  in  the  static  crystal  structure.  Since  no  such  clear
difference are found in the MD simulations also,  we suggested that the real
biologically  active  conformation  of  the  LOV  domain  within  the  whole
phototropin 
H.Neef et al (1996) was reported NINE European plants were selected to br
screned for hypoglycemic activity. Selection criteria were based on traditional
use and litreture reference. have been studied by using Wistar mice. The cancer
has been introduced to the animal the maximum Total extracts of the plants
were prepares by boiling the dreid materials with water or macerating it with
80% ethanol. Male swiss mice were orally loaded with glucose after the extract
had been given by oral gavage.
 John  et  al  (2010) The  methanolic  extract  of  Sida  retusa  Linn.
(Malvaceae),Urena  lobata  Linn.(Malvaceae)and  Triumfetta  rhomboidea  Jacq.
(Teliaceae) roots were found to inhibit lipid peroxidation, scavenge hydroxyl
and superoxide radicals in vitro. The quantity of S.retusa root extract required
for  50%  inhibition  of  lipid  peroxidation,  scavenging  hydroxyl  radical  and
superoxide radical  was 1130.24 ug/ml respectively.  IC 50 of  root  extract  of
U.lobata was 470.60 ug/ml, 1627.35ug/ml and 1109.24 ug/ml for superoxide
radical  scavenging,  hydroxyl  radical  scavenging  and  lipid  peroxidation
respectively. T.rhomboidea root extract required for IC 50 was 336.65 ug/ml,
1346.03 ug/ml and 1004.22 ug/ml for superoxide scavenging, hydroxyl radical
scavenging  and  lipid  peroxidation  respectively.  The  present  investigation
indicated that S. retusa, U.lobata ajaThe methanolic extract of Sida retusa Linn.
(Malvaceae),Urena  lobata  Linn.(Malvaceae)and  Triumfetta  rhomboidea  Jacq.
(Teliaceae) roots were found to inhibit lipid peroxidation, scavenge hydroxyl
and superoxide radicals in vitro. The quantity of S.retusa root extract required
for  50%  inhibition  of  lipid  peroxidation,  scavenging  hydroxyl  radical  and
superoxide radical  was 1130.24 ug/ml respectively.  IC 50 of  root  extract  of
U.lobata was 470.60 ug/ml, 1627.35ug/ml and 1109.24 ug/ml for superoxide
radical  scavenging,  hydroxyl  radical  scavenging  and  lipid  peroxidation
respectively. T.rhomboidea root extract required for IC 50 was 336.65 ug/ml,
1346.03 ug/ml and 1004.22 ug/ml for superoxide scavenging, hydroxyl radical
scavenging and lipid peroxidation respectively. 
Jayankar et  al  (2010)  was investated experimentally the possible antitumor
effect  and  antioxidant  role  of  methanol  extract  of  Triumfetta  rhomboidea
(METR) leaves against Ehrlich ascites carcinoma (EAC) bearing Swiss albino
mice. The METR administered at the doses of 100, 200 mg/kg, in mice for 14
days after 24 hours of tumor inoculation. The effects of METR on the growth of
murine  tumor,  life  span  of  EAC bearing  mice  were  studied.  Hematological
profile  and  liver  biochemical  parameters  (lipid  peroxidation,  antioxidant
enzymes)  were  also  estimated.  Treatment  with  METR  decreased  the  tumor
volume and viable cell count there by increasing the life span of EAC bearing
mice. METR brought back the hematological parameter more or less normal
level. The effect of METR also decreases the levels of lipid peroxidation and
increased the  levels  of  glutathione (GSH),  superoxide dismutase  (SOD)  and
catalase  (CAT).  The  present  work  indicates  that  the  methanol  extract  of
Triumfetta rhomboidea exhibited significant antitumor and antioxidant activity
in vivo. 
PLANT PROFILE
…Triumfetta rhomboidea …
PLANT PROFILE
Rank Scientific Name and Common Name
Kingdom - Plantae – Plants 
Subkingdom - Trachebionta – Vascular plants
Super division - Spermatophyte- Seed plant
Division - Magnoliphyta-Flowering plant
Class - Magnoliopsida – Dicotyledons
Subclass - Dillenilidae.
Order - Malvales.
Family - Tilianceae – Linden family.
Genus - Triumfetta  L.burbark.
Species - Triumfetta rhomboidea Jacq. – Diamond 
burbark.
Vernacular names:
English - Chinese Burr, Burr Bush, Diamond Burrbark.
Tamil - Ottu Pullu.
Hindi - Chiriyari.
Telugu - Bankathuthara
Kannada - Kadu bende.
Botanical Name
Triumfetta rhomboidea.
Family
Tiliaceae (phalsa family)
Description.
It is an erect woody herb or shrub 75- 150 cm in height. Stems glabrous
longitudinally grooved. Leaves simple, alternate;  blade ovate to rhomboid in
shape with 3-5 lobes, sometimes nearly as wide as broad and 2-10 cm long.
Leaf margins irregularly serrate leaf surface softly pubescent with satellite hairs,
blade palmately veined. Flowers small yellow clustered on the leafs axils. Five
yellow, obviate petals about 5 mm long. Stamens 10-15, Fruits a subglobose bur
with the body 3-4 mm in diameter, covered with 75-100 hooked spines 1.0 to
1.5
Part Used : Leafs.
AIM AND OBJECTIVE.
It is divided into following phase- 
PHASE   I : Taxonomical studies.
 Collection of plants.
 Authentication of plants.
 Powdered the leafs.
 PHASE II : Pharmacognostical studies.
 Successively solvent Extraction.
• Alcohol (ethanol).
• Petroleum ether.
• Benzene
• Water.
 Preliminary Phytochemistry screenings.
• Alkaloids
• Saponins.
• Tannins
• Amino acid
• Flavonoids
• Terpenoids
• Protein
• Steroids
PHASE III : Pharmacological studies.
 Acute toxicity studies (as per OECD guidelines)
 Induction of diabetic animal
 Induces diabetic in rats by STZ
 Measuring the body weight
 Measuring the serum glucose level
 Measuring the plasma glucose
 Determination of lipids
o Triglyceride
o Total cholesterol
o HDL
o VLDL
PHASE IV : Result and Documentation.
Evolution of statistical significance result by computer aided
program and systemic documentation. Values were presented as mean SEM 
Data were analyzed using of variance (ANOVA) and group means were 
compared with Turkey’s post hoc Multiple Comparison Test using prism 
software version 5.
P<0.05 is considered as significant. 
Plan of work
 Literature review
Selection of plant
Collection of plant 
Authentication of plant
Powdered the leafs
Extraction of powered plant leafs
Phytochemical Screening      Pharmacological 
Screening
 Alkaloids Acute toxicity studies
 Saponins Diabetic induced by 
STZ
 Tannins Measuring serum glu-
cose
 Flavonoids Measuring  body 
weight
 Terpeniods Determination of 
lipids
 Proteins etc.,
Result and discussion
Conclusion
MATERIALS AND METHOD.
TAXONOMICAL STUDIES.
1) Collection of plants.
Triumfetta  rhomboidea  was  produced  from  the  Botany  Central
council for Research in Ayurvedia and Siddha Govt of India.
The freshly collected sample were thoroughly cleaned and soaked
in  fresh  water  repeatedly  to  separate  mud  particles  sticking  on  to  plant
constituents. The plants constituents collected were cut into small bits of about
2-3 in size. Then the leafs of the plants are powdered with a mechanical grinder.
This  powder  was  subjected  to  various  studies  for  which  the  materials  and
methods which is presented below.
2) Authentication of plant.
The dried whole plant powder of triumfetta rhomboidea was
supplied  and  authenticated  by Chelladurai.v  research  officer  Botany Central
council for Research in Ayurvedia and Siddha Govt of India.
Pharmacognostical studies.
Extraction procedure.
Equal amount of the weighed powder were mixed and placed
in the Soxhlet apparatus by using various solvents.
• Petroleum ether.
• Chloroform.
• Alcohol (ethanol).
• Benzene
• Petroleum ether extraction.
From the  500gm of crude powder  was  extracted  with  2.5
liter of Petroleum ether (60 – 80) by continuous hot percolation
using Soxhlet apparatus. This can be continued up to 24 hours.
Now  the  solvent  petroleum  ether  was  extracted  out  and
filtered and the Soxhlet is removed the obtained residue is stored in
the dissector.
• Chloroform extraction.
From the  500gm of crude powder  was  extracted  with  2.5
liter of chloroform  (60 – 80) by continuous hot percolation using
Soxhlet apparatus. This can be continued up to 24 hours.
Now  the  solvent  petroleum  ether  was  extracted  out  and
filtered and the Soxhlet is removed the obtained residue is stored in
the dissector.
• Alcohol extraction (ethanol)
From the  500gm of crude powder  was  extracted  with  2.5
liter  of  ethanol  (60  –  80)  by  continuous  hot  percolation  using
Soxhlet apparatus. This can be continued up to 24 hours.
Now  the  solvent  petroleum  ether  was  extracted  out  and
filtered and the Soxhlet is removed the obtained residue is stored in
the dissector.
• Benzene extraction 
From the  500gm of crude powder  was  extracted  with  2.5
liter  of  benzene  (60  –  80)  by  continuous  hot  percolation  using
Soxhlet apparatus. This can be continued up to 24 hours. Now the
solvent  petroleum ether  was  extracted  out  and  filtered  and  the
Soxhlet is removed the obtained residue is stored in the dissector.
Chemicals :
 Streptozotocin.
 Glibenclamide
 Petroleum ether
 Ethanol
 Benzene
 Chloroform
 Studies were carried out in albino rats.
PHYTO CHEMICAL SCREENING.
The  plant  may  be  containing  the  following  compound  such  as
carbohydrate, protein, and lipids. That is utilized as food by man. It also
contains the compound like. Tannins, glycosides, alkaloids. Volatiles oils.
The compound that is responsible for lots of medicinal properties
TEST FOR CARBOHYDRATES 
Molish test
 The  sample  powdered  was  added  with  1  ml  of  alpha  naptool
solution along with conc Sulphuric acid solution in the test tube reddish
colour was produced at the junction between 2 liquid this is shows the
presence of carbohydrate.
Fehling test.
To the sample powder was added with both Fehling A and Fehling
B solution and placed in the water bath for a sufficient time. This shows
the brick red colour. It shows the presence of carbohydrate.
Benedicts test.
To the sample powder add 8 drops of benedicts reagents and voil
the sample vigorously for  5  min  it  shows the  red ppt.  this  shows the
presents of carbohydrate.
TEST FOR ALKALOIDS
To the small of stored powder (sample) was taken and add few drops of
hydrochloric acid and filtered.
The filtered was tested with various alkaloid agents.,
Mayer’s reagents:
To a small of above filter add small quantity of Mayer’s reagent to
form cream precipitate. This shows the presence of alkaloids.
Dragendorffs reagents
From the above filter add small amount of Dragendorffs reagents it
forms a orange brown precipitate. This shows the presents of alkaloids.
TEST FOR FLAVONOIDS
To  the  filter  of  the  plant  extract  add  5  ml  of  dilute  ammonia
solution and followed by the addition of concentrated sulphuric acid. It
forms  a  yellow  colour.  It  shows  extract  indicated  the  presence  of
flavonoids.
TEST FOR STEROIDS.
Salkowaski test
Few amount of plant extract was mixed with chloroform and the
same volume of sulphuric acid is  added on it.  Cherry red colour was
obtain in the chloroform layer. This shows the sample contain steroids.
Libbbermann burchatd test:
The extract is dissolved in 2 ml of chloroform 10 drops of acetic
acid and conc.  Sulphuric acid were added. Now the solution becomes
reddish colour then it turns to bluish green colour. This shows the plant
extraction indicates the presents of steroids.
TEST FOR TANNINS.
From few amount of plant extract is treated with vanillin hydrochloric
acid  reagent.  It  forms,  pink  or  red  colour  due  to  the  formation  of
phloroglucinol, it indicate the presence of tannins.
TEST FOR PROTEIN.
Mellon’s reagents.
Mellon’s reagents (mercuric nitrate in nitric acid containing a trace
of nitrous acid) usually yields a white precipitate on addition to a protein
solution which turns red on heating. 
Ninhydrin Test.
From the  sample  solution  add  2  drops  a  freshly prepared
0.2%  ninhydrine  reagent  was  added  to  the  extract  and  heating.
Development of blue colour may indicate the presence of peptide, amino
acid (PROTEIN).
TEST FOR GLYCOSIDES:
Keller- killani test.
From the small quantity of small powder acetic acid was dissolved
and adds few drops of ferric chloride and transferred to the surface of
conc Sulphuric acid. At the junction, reddish brown colour was formed,
which  gradually  becomes  blue  indicates  the  presents  of  cardiac
glycosides.
TEST FOR SAPONINS.
Foam test:
1 ml of extract solution is diluted separately with distilled water to
20 ml and shaken in a graduated cylinder for 15 minutes. A 1 cm layer of
foam indicates the presence of Saponins.
PHARMACOLOGICAL STUDIES.
ACUTE TOXICITY STUDIES.
Acute  toxicity  study  was  carried  out  in  the  albino  rat  on  the
petroleum ether extract of triumfetta rhomboidea plant leafs according to
the OCED guidelines.
The healthy rats has been taken and divided into 4 different groups.
Then  the  petroleum  ether  extract  was  dissolved  in  0.6%  if  sodium
carboxyl  methyl  cellulose  on  equal.  All  the  four  groups  are  named
GROUP I, II, III, IV Accordingly. The drug has been administrated orally
by the following ratio.
 GROUP I 1000 mg/kg.
 GROUP II 300 mg/kg
 GROUP III 50 mg/kg
 GROUP IV 5 mg/kg
The were monitored (general behavioral, neurological, autonomic,
toxic effect and final for death after 24 hr) continuously for every 5 min
and 10 min for  every 1 hour.  There was no morality and no signs of
toxicity and no animal die even in higher dose of our drug (1000mg/kg).
So the extracts were found to be safe at this dose level, and treated with
higher dose of 2000mg/kg of body weight.
INDUCTION OF DIABETICS
Six adult  albino rats weighting 250-300 grams (75-90 days old)
were used for inducing diabetes. The animals were injected by Streptozotocin at
the dose of 60 mg/kg of the body weight intravenously. Streptozotocin induces
diabetes within 3 days by destroying the beta cells. Diabetic animals and non-
diabetic control group were kept in metabolic cages individually and separately
and under feeding and metabolism control. Glucose in the blood of diabetic rats
exceeded  that  of  the  non-diabetic  control  ones.  Food  consumption  was
measured in terms of (gr.), water consumption was measured in terms of (ml)
and urine volume was measured in terms of (ml) on a daily basis while every 2-
4 weeks in 80 days the levels of C-peptide, insulin and glucose in blood serum
were also measured, so that chemical diabetes was verified in rats injected with
Streptozotocin 
ASSESSMENT OF DIABETIC.
Diabetic was conformed after 48 hr of streptozotocin injection, the blood
samples were collected through retro orbital puncture and plasma glucose level
were estimated by enzymatic GOD POD diagnostic kit method. The rat having
fasting plasma glucose levels more than 250 mg/dL were selected and used for
this study.
EVALUATION  OF  EXTRACT  ON  STREPTOZOTOCIN  INDUCED  DIABETIC
RATS.
The albino rats on either sex have been selected for the experimental study. The
weight of the should be around 170-240 gm. The animals are divided into six
groups. Each group has 6 animals.
Group  1was  kept  as  normal  (normal  rat)  received  only
distilled water; group 2 was kept as negative control, Streptozotocin induced
and received only water. Group 3 was treated with glibenclamide (10mg/kg)
Group 4, 5 and 6 is diabetic induced rat and treated with 100mg/kg,200mg/kg
and 400mg/kg b.w of petroleum ether extract of triumfetta rhomboidea.   
Table 2-Evaluation of extract on Streptozotocin induced diabetic Rats.
S no Groups Treatment
1 Group I Normal control
2 Group II Diabetic control
3 Group III Diabetic + glibenclamide(10 mg/kg)
4 Group IV Diabetic + Extract  (100 mg/kg)
5 Group V Diabetic + Extract  (200 mg/kg)
6 Group VI Diabetic + Extract  (400 mg/kg)
Triumfetta rhomboidea. Extract was administered for 21 days at  a two
different dose levels 100, 200mg/kg of Triumfetta rhomboidea.    Extract
made  in  aqueous  and given orally.  The  blood was  collected  by  sinus
orbital under the light diethyl ether anesthesia. The blood was centrifuged
at 3000 rpm for 10 minutes. Body weight glucose was analyzed every
week and lipid and lipoprotein profile from serum (TC, TG, HDL, LDL,
VLDL.) were analyzed after 21 days.
OBSERVATION 
Serum glucose level estimation (initial and final)
Body weight of the albino rats (initial and final)
ESTIMATION OF GLYCOSYLATED HEMOGLOBIN CONTENT
Glycosylated peptides are elevated several folds in diabetics. The use of
the  glycosylated  hemoglobin  (HbA1c)  assay  for  long  term  diabetic
monitoring of diabetic control is gaining much wider use and acceptance.
The hematological parameter glycosylated hemoglobin was determined
by standard laboratory techniques.
ESTIMATION OF LIPIDS.
TOTAL CHOLESTEROL
The cholesterol in serum was estimated by using ecoline diagnostic
kit. Cholesterol and its ester were released from lipoprotein by detergents
cholesterol  estrates  hydrolyses  the  ester  the  sub subsequent  enzymatic
oxidation by cholesterol oxidize, Hydrogen peroxidase was formed. This
was  converted  into  colored  quininemine  in  a  reaction  with  4-
aminopyantipyrine and phenol catalyses by peroxidase the observance of
the sample and of the standard was measured against the reagent blank
value at 546nm. Cholesterol level in serum was expressed as mg/dL.
TRIGLYCERIDES.
The triglyceride level was estimated by using Ecoline diagnostic kit.
Triglyceride       Lipase  Glycerol + Fatty acid
Triglyceride GK Glycerol + Fatty acid
Glycerol 3 phosphate + O2 GPO    Dihydroxy acetone phosphate+  
H2O2
2H2O2 + Aminoantipyrine + 4 chlorophenol   POD       Chinonimine + 
4H2O
The absorbance of the sample and of the standard was measured against
reagent blank value at 546nm. Triglyceride level in serum was expressed
as mg/dL.
HDL CHOLESTEROL
The cholesterol was separated from the serum after precipitation of
LDL  cholesterol  by  phosphotungstic  acid  precipitating  reagent.  The
supernatant. After centrifugation was estimated using Ecoline diagnostic
kit. The absorbance of sample and of the standard was measures against
the reagent blank value at 546 nm. HDL cholesterol level in serum was
expressed as mg/dL.
LDL CHOLESTEROL.
The LDL Cholesterol is calculating by following formula
LDL Cholesterol = Total cholesterol – [HDL cholesterol – Triglyceride / 5].
LDL cholesterol level in the plasma is calculated and expressed in the
unit of mg/dL.
VLDL CHOLESTEROL.
The VLDL Cholesterol is calculating by following formula
VLDL Cholesterol = Total cholesterol – HDL cholesterol – Triglyceride-LDL.
RESULT AND DISCUSSION.
Preliminary phyto chemical screening.
Triumfetta rhomboidea was subjected various chemical tested as per the
standard methods for the identification of the various constituents. The result if
this phyto chemical analysis is listed below.
Table-3 Qualitative phyto chemical screening of Triumfetta rhomboidea  .
Plant
constituent
Petroleum
ether
extract
Benzene extract Ethanol
extract
Chloroform
extract.
Steroids + + + +
Carbohydrate + + + +
Flavonoids + + + -
Proteins and
amino acids - - - -
Glycosides + + - +
Alkaloids - - - -
Saponins + - + +
Volatile oil + + + +
Tannins + + + +
      “+” Presence,  “-” Absence.
ACUTE TOXICITY STUDIES.
Acute toxicity studies on the albino rats show no morality at a dose of
2000mg/kg, during a time period of 14 days. During the study, no noticeable
were seen in the rats. This help to predict that it does not contain any type of
toxicity and it is full safe. So 100 mg/kg b.w (1/20th and 200mg/kg b.w (1/0th)
were selected of that dose for the further study.
Effect of  Triumfetta rhomboidea  on serum glucose levels
Streptozotocin  treatment  will  produce  significant  increase  in  serum
glucose  level  with  respective  normal  control  group.  The  administration  of
triumfetta  rhomboidea  extract  100mg/kg,  200  mg/kg  and  400mg/kg  and
glibenclamide 10 mg/kg significantly reversed the increase in serum glucose
concentration in Streptozotocin induced rats. The extract changes in the serum
glucose level are shown in the table.
Effect of  Triumfetta rhomboidea  on body weight.
There was gradual increase in body weight in normal control while the
diabetic control continues to lose the weight. However treated diabetic group
gained 6.25%, 8.24% as compared with the diabetic control and diabetic treated
towards normal range. Extract changes in the body weight shows in the table
Effect of  Triumfetta rhomboidea  on glycosylated hemoglobin.
There  was  a  significant  increases  in  glycosylated  hemoglobin  level  is
observed in diabetic rats. The level of glycosylated hemoglobin was decreased
significantly  in  extract  and  glibenclamide  treated  rats  compared  to  diabetic
control rats. This can be shown in the table.
Effect of  Triumfetta rhomboidea  on serum lipid and lipoprotein.
STZ  diabetic  rats  group  were  found  to  have  significantly  increased
VLDL, LDL, TG, TC level and markedly decreased HDL levela as compared to
normal control group. Treatment with triumfetta rhomboidea extract 100mg/kg,
200 mg/kg and 400mg/kg reduced significantly VLDL, LDL, TG, TC, levels
and markedly increased  HDL level  as  compared  to  diabetic  control  groups.
Positive control was significantly preventing the increasing the serum TC, TG,
LDL, VLDL and decreasing the HDL level as compared to diabetic group. Thus
the  extract  treatment  restored  all  these  changes  near  to  normal  value.  This
change in serum is listed on the table.
Table - 4 -Effect of Triumfetta rhomboidea extract on serum glucose 
level in normal control and STZ induced diabetic rats
S.NO TREATMENT
SERUM GLUCOSE LEVEL
Initial Final
1. Normal control 90.97±1.47 89.52±2.16
2 Diabetic control 259.3±3.51 405.3±1.265
3. Diabetic+ Glibenclamide 10mg/kg 267.8±3.15 129.5±1.035
4. Diabetic+ Extract 100mg/kg 238.0±2.65 325.2±2.46
5. Diabetic+ Extract 200mg/kg 241.9±1.25 224.2±2.49
6. Diabetic+ Extract 400mg/kg 242.1±3.21 140.2±3.19
All values are expressed in MEAN ± SEM (n=6)
Table -5-Effect of Triumfetta rhomboidea extract on body weight in normal
control and STZ induced diabetic rats.
s/no TREATMENT BODY WEIGHT
Initial Final
1. Normal control 241.9±3.51 275±1.95
2. Diabetic control 248.9±1.43 190±1.64
3. Diabetic + Glibenclamide. 243.5±1.53 275.8±1.65
4. Diabetic+ Extract 100 243.2±2.51 282.8±2.76
5. Diabetic+  Extract 200 250.5±3.23 301.2±2.82
6. Diabetic + Extract 400 241.6±3.84 261.1±1.44
All value are expressed mean ±SEM (n=6) 
P<0.001, as compared to diabetic control 
P<0.001 as compared to Normal control.
Table in parenthesis indicate % fall in body weight as compared to initial value.
Table -6-Effect of Triumfetta rhomboidea extract on serum lipid and lipoprotein
profile in normal control and STZ induced diabetic rats.
S.NO Treatment TC(mg/Dl)
TG(mg/Dl
)
HDL(mg/Dl
)
LDL(mg/Dl
)
VLDL
(mg/Dl)
1. Normal control 88.6±4.54
60.01±1.
6 41.5±1.32
92.5±1.0
7
26.5±1.
32
2. Diabetic control 231±7.45 131±4.21 21.3±1.42 131±1.67
52.3±2.
18
3.
Diabetic +
Glibenclamide
(10mg/kg)
141±2.35 101±2.90 45.6±1.48 102±2.06
35.2±1.
65
4
Diabetic + extract
(100mg) 136±3.95 116±2.62 48.3±2.01 113.±2.62
41.3±1.
56
5.
Diabetic + extract
(200mg) 132±3.52 112±3.01 45.4±1.30 102±2.12
39.1±2.
06
6.
Diabetic + extract
(400mg) 89.3±1.03
62.3±3.6
5 39.3±1.37
98.6±1.6
8
23.71±2
.18
All value are expressed as mean ±SEM (n=6)
P<0.001, as compared to diabetic control 
P<0.001 as compared to Normal control.
Table in parenthesis indicate % fall in body weight as compared to initial value.
Serum glucose level
The Figure showed of Triumfetta rhomboidea extract serum glucose level in 
normal control and STZ induced diabetic rat. Values are expressed as mean ± 
SEM of 6 animals in each group.
Body weight of the animal
The Figure showed of  Triumfetta rhomboidea extract on Body weight in
normal control and STZ induced diabetic rat. Values are expressed as mean
± SEM of 6 animals in each group
88.6
231
141 136 132
89.3
Total cholestrol
The Figure showed of Triumfetta rhomboidea extract on total cholesterol in
normal control and STZ induced diabetic rat. Values are expressed as mean
± SEM of 6 animals in each group
The Figure showed of  Triumfetta rhomboidea extract on triglycerides in
normal control and STZ induced diabetic rat. Values are expressed as mean
± SEM of 6 animals in each group
The  Figure  showed  of  Triumfetta  rhomboidea extract  on  High  density
lipids in normal control and STZ induced diabetic rat. Values are expressed
as mean ± SEM of 6 animals in each group
The Figure showed of Triumfetta rhomboidea extract on low density lipids 
in normal control and STZ induced diabetic rat. Values are expressed as 
mean ± SEM of 6 animals in each group
The Figure showed of Triumfetta rhomboidea extract on very low density
lipids in normal control and STZ induced diabetic rat. Values are expressed
as mean ± SEM of 6 animals in each group.
DISCUSSION
Diabetes is a common chronic ailment for which the patient has to take insulin
to maintain the blood sugar level.  It  is  interesting to see how the triumfetta
rhomboidea extract tackles this problem. It corrects the function of pancreas,
stimulating it to produce insulin in the natural way, which in turns way, which I
turn  maintain  the  blood  sugar  level.  Triumfetta  rhomboidea  revitalizes  and
rejuvenates the organs, the dysfunction of which is causing the disease. This
bring back normal functioning of the organs. It is also maintaining the healthy
state body. Since no artificial chemical are involved, it doesn’t cause any side
effects
Qualitative  Phytochemical  screening  and  ethno  botanical  survey  on  the
triumfetta rhomboidea are vaulted the presented of certain phyto constitutions
such  alkaloids,  tannins,  carbohydrates,  glycosides,  protein  and  amino  acids,
phytosterol, high amount of terpeniods
The  phyto  chemical  constituents  such  as  glycosides,  tannins,  triterpenoids,
flavonoids, alkaloids may be linked to the anti diabetic activity.
To check the safety profile of the triumfetta rhomboidea extract it was subjected
to  the  acute  toxicity  study which  conformed  the  absence  of  any toxicity  or
mortality  at  the  higher  dose  of  2000mg/kg.  Thus  the  triumfetta  rhomboidea
extract  can  be  classified  as  a  safe  drug  category  according  to  the  Global
harmonized Classification System quoted in the OECD guidelines 1996.
Based  on  the  articles  toxicity  studies  two  dose  level  were  selected  for  the
evolution  of  various  pharmacological  studies  properties  (100,200and
400mg/kg).
Diabetic  mellitus  (DM)  is  an  endocrine  disorder  in  which  the  glucose
metabolism is  impaired  because  of  total  loss  of  insulin  after  destruction  of
pancreatic  beta  cells  or  because  of  inadequate  release  of  insulin  from  the
pancreatic  cells  of  beta  cells.  The  fundamental  mechanism  underlying
hyperglycemia involved over population and decreases utilization of glucose by
the  tissue.  In  the  presence  study  was  observed  that  whether  the  triumfetta
rhomboidea extract have the effect of lipid profile, anti oxidant system or not
and in addition to  its  antihyperglycaemic action of  STZ induced diabetic  in
albino rats
Streptozotocin a beta cytotoxin induces diabetic in a wide variety of  animal
species including rats by selectively damaging the insulin secreting beta cells of
pancreas i.p injection of STZ produces fragmentation of DNA of beta cells of
pancreas  which  stimulates  poly  (ADP ribose  and  deflects  NDA ultimately
leading of destruction of beta cells and it is evidenced by clinical symptoms of
hyperglycemia.
Dose dependant of the effect of the glibenclamide showed rapid normalization
of blood glucose due to its insulin releasing effects.
In our present study there was a significant weight gain triumfetta rhomboidea
treated  the  diabetic  rats  compared  with  the  normal  control  rats  and  this
observation shows anabolic effect of the triumfetta rhomboidea extract on body
weight on the diabetic rats.
Hyperglycemia  and  insulin  resistance  both  seem  to  have  important  in  the
pathogenesis  of  macro  vascular  complications.  Diabetes  mellitus  causes  a
disturbance  in  the  uptake  of  glucose  as  well  as  glucose  metabolism.  The
hyperglycemia in the diabetes might inhibit tissue repair in the macro vascular
beds. In the present study of triumfetta rhomboidea extract treated group shows
hypoglycemic  activity  and  it  confirms  the  presence  of  the  anti-  diabetic
activity.3
Sulfonylurea such as glibenclamide is often used as a standard drug in the STZ
induced diabetic to compare to the efficacy of antihyperglycaemic compound.
In  study there was a significant elevation in blood glucose level in the diabetic
control  group  as  compared  with  normal  animal.  The  triumfetta  rhomboidea
extract treated group exhibited significant reduction of fasting plasma glucose
level as compared to the diabetic control group. Over production of glucose by
means  excessive  hepatic  glycogenolysis  and  gluconeogenesis  is  one  of  the
fundamental basis of hyperglycemia in diabetes mellitus.
Increased glycation of protein has been found to be consequence of diabetic
complication.  A number  of  proteins  including hemoglobin are Glycated to  a
greater  degree  in  diabetic  glycosylated  hemoglobin  (HbA1c)  is  the
measurement  of  the mean blood glucose level  over the previous 6-8 weeks,
during the life span of RBC. It has been shown to be an important parameter of
chronic glycameic control in patient with diabetic mellitus (DM), an elevated
HbA1c almost always indicted DM. in our present study glycation of protein is
significantly lowered by the treatment with triumfetta rhomboidea extract.
The  most  common  observed  lipid  abnormalities  in  diabetics  are
hypertriglyceridemia  and  hypercholesterolemia.  A marked  increase  in  total
cholesterol and decrease in HDL cholesterol have been observed in diabetics
control rats. Insulin deficiency results in failure to activate the lipoprotein lipase
thereby causing  hypertriglyceridemia.  There  was  a  significant  control  of  the
level of serum lipids in triumfetta rhomboidea extract treated diabetic rats. In
diabetes, LDL carries cholesterol to the peripheral tissue where it is deposited,
where HDL transports cholesterol from peripheral tissue to the liver and this
aids its excretion. Hence increase in LDL is atherogenic. In our present study,
there was a significant decrease in triglyceride LDL and T.C levels, where as
there was a significant increase in the HDL level.
SUMMARY AND CONCLUSION
The presented study is an attempt to investigate the effect of petroleum ether
extract of triumfetta rhomboidea on Streptozotocin induced diabetic in albino
rats.
The  Phytochemical  study  was  screening  showed  the  presence  of  tannins,
carbohydrate, Flavonoids, alkaloids, reducing sugar and amino acid which is
responsible for the anti diabetic activity.
 The animals were induced with STZ at a dose of 55mg/kg intraperatoneal and
the diabetic animals were treated with triumfetta rhomboidea extract (100, 200,
400mg/kg) for 21 days orally. The serum glucose, body weight lipid profile,
liver glycogen were measured from the pancreas homogenate were measured
which showed significant activity.
The finding of the presence investigation suggests the triumfetta rhomboidea
extract  has  potential  for  its  evaluation  as  protective  agents  against  toxicity
induced by Streptozotocin.
Clinical  assessments  of  triumfetta  rhomboidea  extract  determination  of
underlying mechanism of the protective effects in interesting topics requiring
further study 
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COMMITEE FOR THE PURPOSE OF CONTROL AND SUPERVISON OF
EXPRIMENT ON ANIMAL.
Reg:
Ref No: IAE 1012/c/06/CPCSEA-Corres-2013-2014          
21.06.2013
Sub: Approval of animal studies – project submitted for clearance –Resolution passed by
Institutional Animal Ethical Committee held 21st June 2013
Sir,
With reference  to the subject  cited above,  please  find the enclosed list  of  project
cleared  for  the  animal  studies  by the  institutional  animal  committee  of  RVS College  of
Pharmaceutical Science, in its meeting held on 21st June 2013 at the college premises.
Dr.D.Benito Johnson Dr .R. Venkatanarayanan
Secretary Member Principal/Chairman IAEC
IAEC
No. of resolution Passed -55.
Resolution No: 55
It is resolved to pass the clearance for the animal study of the project  “Anti
diabetic activity of  Triumfetta rhomboidea  on streptozotocin induced diabetic in
albino  rats”  submitted  by  Padma  Vinayaka  Moorthy.R  Department  of
pharmacology,  RVS  College  of   pharmaceutical  Science,  Sulur,  Coimbatore-  641
402,Tamilnadu.
